These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11842228)

  • 1. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation.
    Davis BB; Thompson DA; Howard LL; Morisseau C; Hammock BD; Weiss RH
    Proc Natl Acad Sci U S A; 2002 Feb; 99(4):2222-7. PubMed ID: 11842228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition.
    Davis BB; Morisseau C; Newman JW; Pedersen TL; Hammock BD; Weiss RH
    J Pharmacol Exp Ther; 2006 Feb; 316(2):815-21. PubMed ID: 16221742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
    J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration.
    Wang Q; Huo L; He J; Ding W; Su H; Tian D; Welch C; Hammock BD; Ai D; Zhu Y
    Am J Physiol Heart Circ Physiol; 2015 Dec; 309(11):H1894-903. PubMed ID: 26453326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.
    Ng VY; Morisseau C; Falck JR; Hammock BD; Kroetz DL
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2462-8. PubMed ID: 16917105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors.
    Fang X; Hu S; Watanabe T; Weintraub NL; Snyder GD; Yao J; Liu Y; Shyy JY; Hammock BD; Spector AA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):260-70. PubMed ID: 15798002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea.
    Watanabe T; Morisseau C; Newman JW; Hammock BD
    Drug Metab Dispos; 2003 Jul; 31(7):846-53. PubMed ID: 12814960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels.
    Olearczyk JJ; Field MB; Kim IH; Morisseau C; Hammock BD; Imig JD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1307-14. PubMed ID: 16772540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells.
    Kim HS; Kim SK; Kang KW
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable EET urea agonist and soluble epoxide hydrolase inhibitor regulate rat pulmonary arteries through TRPCs.
    Liu Y; Wang R; Li J; Rao J; Li W; Falck JR; Manthati VL; Medhora M; Jacobs ER; Zhu D
    Hypertens Res; 2011 May; 34(5):630-9. PubMed ID: 21307870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis.
    Gurung AB; Mayengbam B; Bhattacharjee A
    Comput Biol Chem; 2018 Jun; 74():1-11. PubMed ID: 29522918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.
    Revermann M; Barbosa-Sicard E; Dony E; Schermuly RT; Morisseau C; Geisslinger G; Fleming I; Hammock BD; Brandes RP
    J Hypertens; 2009 Feb; 27(2):322-31. PubMed ID: 19226702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A soluble epoxide hydrolase inhibitor--8-HUDE increases pulmonary vasoconstriction through inhibition of K(ATP) channels.
    Liu Y; Zhang J; Yu L; Cao F; Rao J; Li J; Jiang C; Falck JR; Jacobs ER; Zhu D
    Pulm Pharmacol Ther; 2012 Feb; 25(1):69-76. PubMed ID: 22155000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.
    Imig JD
    Cardiovasc Drug Rev; 2006; 24(2):169-88. PubMed ID: 16961727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
    Fang X
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):67-72. PubMed ID: 18221075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.
    Sun D; Cuevas AJ; Gotlinger K; Hwang SH; Hammock BD; Schwartzman ML; Huang A
    Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1146-53. PubMed ID: 24561863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble epoxide hydrolase inhibitor, TPPU, attenuates progression of atherosclerotic lesions and vascular smooth muscle cell phenotypic switching.
    Kim SA; Lee AS; Lee HB; Hur HJ; Lee SH; Sung MJ
    Vascul Pharmacol; 2022 Aug; 145():107086. PubMed ID: 35752378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nox4 and soluble epoxide hydrolase synergistically mediate homocysteine-induced inflammation in vascular smooth muscle cells.
    Liu X; Qin Z; Liu C; Song M; Luo X; Zhao H; Qian D; Chen J; Huang L
    Vascul Pharmacol; 2019 Sep; 120():106544. PubMed ID: 30610956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.
    Shaik JS; Ahmad M; Li W; Rose ME; Foley LM; Hitchens TK; Graham SH; Hwang SH; Hammock BD; Poloyac SM
    Am J Physiol Heart Circ Physiol; 2013 Dec; 305(11):H1605-13. PubMed ID: 24043255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
    Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
    Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.